CROSS COUNTRY HEALTHCARE INC 8-K

What Happened

• Cross Country Healthcare, Inc. (CCRN) filed a definitive proxy statement with the SEC on June 15, 2026 for a proposed merger in which KL Criss Cross Merger Sub, Inc. will merge into Cross Country and Cross Country will become a wholly‑owned subsidiary of KL Criss Cross Intermediate, LLC (Parent).
• A special meeting of stockholders to vote on the Merger is scheduled for July 16, 2026 at 12:00 p.m. ET; holders of record as of the close of business on June 12, 2026 are eligible to vote. The company expects to complete the Merger in the third quarter of 2026, subject to customary closing conditions and stockholder approval.

Key Details

• Two lawsuits challenging the proxy (Malone v. Cross Country, filed June 23, 2026, and Walsh v. Cross Country, filed June 24, 2026 in New York Supreme Court) allege the proxy is materially incomplete and seek to enjoin the Merger; the company says the claims lack merit but will voluntarily supplement the proxy.
• The company will supplement its proxy with disclosures including possible post‑closing discussions: on May 14, 2026 Knox Lane (the sponsor) initiated conversations with executives Mr. Burns and Ms. Ball about possible consulting arrangements and with Mr. Clark about a board role.
• Financial valuation inputs disclosed in the supplement: estimated net cash of approximately $106.2 million and ~33.006 million fully‑diluted shares used in BofA valuation work; BofA applied EV/EBITDA ranges of 4.8x–7.5x (selected publicly traded comps) and 9.0x–11.5x (precedent transactions), and DCF assumptions (terminal growth 3.0%–4.0%, discount rates 9.0%–11.0%).
• The company reiterates forward‑looking risk factors and directs investors to read the definitive proxy and related SEC filings for full information.

Why It Matters

• Stockholder approval at the July 16 meeting is required to close the transaction; litigation over the proxy could delay or complicate the timeline and may affect the ability to complete the Merger as planned.
• The supplemental disclosures add detail on potential post‑closing arrangements for executives and on valuation assumptions (net cash, share count, multiples and DCF inputs) that investors should review when assessing the fairness and price of the transaction.
• Retail investors should read the full definitive proxy and monitor developments (including any court actions or additional supplements) before voting, since these filings contain the facts and risks that could materially affect timing and value.